進階搜尋


下載電子全文  
系統識別號 U0026-0409201314033400
論文名稱(中文) PPAR-r與RBP4基因多型性對多囊性卵巢症候群患者之代謝表現型的影響
論文名稱(英文) Effects of PPAR-r and RBP4 polymorphisms on the metabolic phenotypes in patients with polycystic ovary syndrome
校院名稱 成功大學
系所名稱(中) 臨床醫學研究所
系所名稱(英) Institute of Clinical Medicine
學年度 101
學期 2
出版年 102
研究生(中文) 蔡岡廷
研究生(英文) Kang-Ting Tsai
學號 S97971125
學位類別 碩士
語文別 英文
論文頁數 31頁
口試委員 指導教授-蔡曜聲
指導教授-吳孟興
口試委員-林聖翔
口試委員-陳勝咸
中文關鍵字 多囊性卵巢  基因多型  PPAR-r C1431T 
英文關鍵字 polycystic ovary syndrome  single nucleotide polymorphism  PPAR-r C1431T 
學科別分類
中文摘要 研究目標: 本病例對照研究目的為探討PPAR-γ與RBP4基因多型性與多囊性卵巢患者之各種代謝表現型的關聯性。
材料與方法: 我們召集介於18至45歲的多囊性卵巢患者與正常對照組,並對他們進行基因檢測以確認PPAR-γ基因中的單核苷酸多型性C1431T與Pro12Ala以及RBP4基因中的803GA與7542Tdel基因型。患者與對照組的血液生化與荷爾蒙檢測也同時被進行,並比較兩種基因型與各種表現型的關聯性。
結果: 我們共招集了155位多囊性卵巢患者與151位對照組個案。實驗中的各種單核苷酸多型性在實驗組與對照組中的分佈並沒有顯著差異。在患者之中,我們發現帶有C1431T之CT或TT基因型者,具有顯著較高的胰島素敏感性指標(包含空腹血糖與胰島素比值與QUICKI)。而帶有帶有Pro12Ala之Pro/Ala基因型的患者,其血中總膽固醇顯著較低。以上這些關聯性,在我們排除了較胖的患者之後依舊顯著,但在正常對照組中確卻沒有類似關聯性。
結論: 我們的結果顯示PPAR-γ C1431T基因多型性可能與多囊性卵巢患者的胰島素敏感度有相關性。
英文摘要 Objective: The aim of this case-control study was to investigate the association between PPAR-γ and RBP4 gene polymorphisms and the metabolic phenotypes of patients with polycystic ovary syndrome (PCOS).
Materials and Methods: Women with PCOS and control group who were 18-45 years old were enrolled. Genotypes of four functional single nucleotide polymorphisms (SNPs), the C1431T and Pro12Ala of PPAR-γ2 and 803GA and 7542Tdel of RBP4 were determined by using direct sequencing. Biochemical laboratory parameters were collected for hormonal and metabolic evaluation.
Results: We included 155 PCOS cases and 151 control subjects. The genotype distributions of the SNPs in the PCOS group were not significantly different from that of the control group. Significantly higher fasting glucose to insulin ratio and quantitative insulin-sensitivity check index (QUICKI) were found in PCOS cases with CT/TT genotype. Subjects with Pro/Ala genotype had significantly lower serum total cholesterol level. These associations were still significant after excluding obese PCOS cases, but can’t be found in control group.
Conclusion: These results suggest that the PPAR-γC1431T polymorphisms may be associated with insulin sensitivity in PCOS patient but not normal subjects.
論文目次 Contents
1. Abstract........................................................................................................................................3
2. Abstract (Chinese).......................................................................................................................4
3. Acknowledgement........................................................................................................................5
4. Introduction..................................................................................................................................8
5. Material and Method.................................................................................................................10
I. Study subjects.....................................................................................................................10
II. Biochemical tests................................................................................................................10
III. Genotyping.........................................................................................................................11
IV. Statistical analysis.............................................................................................................11
6. Results.........................................................................................................................................13
I. Clinical and biochemical characteristics of the study population.....................................13
II. The genetic frequencies of PPARγ and RBP4 polymorphisms..........................................14
III. The association between PPARγ polymorphisms and metabolic phenotypes...................15
7. Discussion...................................................................................................................................18
8. References...................................................................................................................................21
參考文獻 1. Teede H, Deeks A, Moran L 2010 Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC medicine 8:41
2. Dasgupta S, Reddy BM 2008 Present status of understanding on the genetic etiology of polycystic ovary syndrome. Journal of postgraduate medicine 54:115-125
3. Lin YS, Tsai SJ, Lin MW, Yang CT, Huang MF, Wu MH 2011 Interleukin-6 as an early chronic inflammatory marker in polycystic ovary syndrome with insulin receptor substrate-2 polymorphism. Am J Reprod Immunol 66:527-533
4. Tsai YS, Maeda N 2005 PPARgamma: a critical determinant of body fat distribution in humans and mice. Trends in cardiovascular medicine 15:81-85
5. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR 1997 Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochemical and biophysical research communications 241:270-274
6. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J 1998 A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature genetics 20:284-287
7. Tai ES, Corella D, Deurenberg-Yap M, Adiconis X, Chew SK, Tan CE, Ordovas JM 2004 Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. Journal of lipid research 45:674-685
8. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M 2000 Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochemical and biophysical research communications 268:178-182
9. Knouff C, Auwerx J 2004 Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocrine reviews 25:899-918
10. Kannisto K, Sutinen J, Korsheninnikova E, Fisher RM, Ehrenborg E, Gertow K, Virkamaki A, Nyman T, Vidal H, Hamsten A, Yki-Jarvinen H 2003 Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 17:1753-1762
11. Schindler K, Haider D, Wolzt M, Rieger A, Gmeinhart B, Luger A, Nowotny P, Ludvik B 2006 Impact of antiretroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects. European journal of clinical investigation 36:640-646
12. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB 2005 Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436:356-362
13. Yang B, Lin P, Carrick KM, McNulty JA, Clifton LG, Winegar DA, Strum JC, Stimpson SA, Pahel GL 2005 PPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF rats. Biochemical and biophysical research communications 334:176-182
14. van Hoek M, Dehghan A, Zillikens MC, Hofman A, Witteman JC, Sijbrands EJ 2008 An RBP4 promoter polymorphism increases risk of type 2 diabetes. Diabetologia 51:1423-1428
15. Group. REA-SPCW 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 81:19-25
16. 2004 Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363:157-163
17. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb SS, Auwerx J, Uusitupa M, Laakso M 1999 Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 84:3708-3712
18. Yang LL, Hua Q, Liu RK, Yang Z 2009 Association between two common polymorphisms of PPARgamma gene and metabolic syndrome families in a Chinese population. Archives of medical research 40:89-96
19. Meirhaeghe A, Amouyel P 2004 Impact of genetic variation of PPARgamma in humans. Molecular genetics and metabolism 83:93-102
20. Mohamed MB, Mtiraoui N, Ezzidi I, Chaieb M, Mahjoub T, Almawi WY 2007 Association of the peroxisome proliferator-activated receptor-gamma2 Pro12Ala but not the C1431T gene variants with lower body mass index in Type 2 diabetes. Journal of endocrinological investigation 30:937-943
21. Doney AS, Fischer B, Cecil JE, Boylan K, McGuigan FE, Ralston SH, Morris AD, Palmer CN 2004 Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 47:555-558
22. He J, Wang L, Liu J, Liu F, Li X 2012 A meta-analysis on the association between PPAR-gamma Pro12Ala polymorphism and polycystic ovary syndrome. Journal of assisted reproduction and genetics 29:669-677
23. Chae SJ, Kim JJ, Choi YM, Kim JM, Cho YM, Moon SY 2010 Peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha gene polymorphisms in Korean women with polycystic ovary syndrome. Gynecologic and obstetric investigation 70:1-7
24. Yilmaz M, Ergun MA, Karakoc A, Yurtcu E, Cakir N, Arslan M 2006 Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol 22:336-342
25. Hahn S, Fingerhut A, Khomtsiv U, Khomtsiv L, Tan S, Quadbeck B, Herrmann BL, Knebel B, Muller-Wieland D, Mann K, Janssen OE 2005 The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clinical endocrinology 62:573-579
26. Tok EC, Aktas A, Ertunc D, Erdal EM, Dilek S 2005 Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-gamma2 Pro12Ala genotype. Hum Reprod 20:1590-1595
27. Antoine HJ, Pall M, Trader BC, Chen YD, Azziz R, Goodarzi MO 2007 Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertility and sterility 87:862-869
28. Yildizhan R, Ilhan GA, Yildizhan B, Kolusari A, Adali E, Bugdayci G 2011 Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome. Fertility and sterility 96:246-250
論文全文使用權限
  • 同意授權校內瀏覽/列印電子全文服務,於2015-09-10起公開。
  • 同意授權校外瀏覽/列印電子全文服務,於2015-09-10起公開。


  • 如您有疑問,請聯絡圖書館
    聯絡電話:(06)2757575#65773
    聯絡E-mail:etds@email.ncku.edu.tw